Taken together, these results suggest that CEBPD-driven immune suppression in APOE+ macrophages contribute to ICB resistance in ccRCC, highlighting CEBPD as a potential therapeutic target to overcome immunotherapy resistance. Here, CEBPD is linked to nonpapillary renal cell carcinoma.